［Abstract］　Adenomyosis is a benign gynecological condition characterized by the invasion of endometrial glands and stroma into the myometrium. It is closely associated with abnormal uterine bleeding, dysmenorrhea, chronic pelvic pain, infertility, and adverse pregnancy outcomes, significantly impairing the patients′ quality of life. Transvaginal ultrasound(TVUS), owing to its convenience, cost-effectiveness, and capacity for dynamic observation, has become the first-line imaging modality for diagnosing adenomyosis. With the continuous advancement of ultrasound imaging and image processing technologies—including three-dimensional(3D) ultrasound, contrast-enhanced ultrasound and elastography—as well as the establishment of the standardized diagnostic system for Morphological Uterus Sonographic Assessment(MUSA), the diagnostic accuracy of ultrasound for adenomyosis has been substantially improved. Furthermore, its application is progressively expanding into disease typing, severity grading, and therapeutic efficacy monitoring. This review summarizes the latest research progress in the ultrasound diagnosis of adenomyosis.]]> 2026/9/30 9:59:14 1, Liu Jie¹, Li Xiaodong²]]> He Xiaojing¹, Liu Jie¹, Li Xiaodong² 6true ［Abstract］　Adenomyosis is a common benign disease in women of reproductive age, characterized pathologically by the infiltration of endometrial glands and stroma into the myometrium. For patients with fertility aspirations, the therapeutic paradigm has shifted from solely pursuing complete lesion excision to a comprehensive approach that balances lesion burden control, preservation of uterine structural integrity, and improvement of pregnancy outcomes. This review systematically summarizes current advancements in the diagnostic assessment of adenomyosis, fertility-sparing surgical techniques, and minimally invasive interventional therapies, including high-intensity focused ultrasound(HIFU), uterine artery embolization(UAE), and radiofrequency ablation(RFA), with a focus on their efficacy and safety. Special emphasis is placed on factors influencing reproductive outcomes and strategies for patient selection. Formulating individualized strategies based on disease type, patient characteristics, and fertility goals, together with standardized perioperative management and consideration of obstetric risks such as uterine rupture and placenta accreta spectrum disorders, is crucial for improving pregnancy outcomes.]]> 2026/9/30 9:59:14 1, Liang Zhiqing²]]> Liang Xiaolong¹, Liang Zhiqing² 5true ［Abstract］　Adenomyosis is a common benign gynecological disease that can lead to dysmenorrhea, menorrhagia, chronic pelvic pain, and infertility. Although traditional hysterectomy provides definitive symptom relief, it fails to meet the treatment needs of young patients and those with a desire to preserve the uterus or maintain fertility.In recent years, thermal ablation technologies such as high-intensity focused ultrasound(HIFU), radiofrequency ablation(RFA), and microwave ablation(MWA) have gradually been applied to the treatment of adenomyosis, providing new options for uterus-sparing therapy. Existing studies indicate that image-guided thermal ablation can effectively alleviate dysmenorrhea and menorrhagia, reduce lesion size and uterine volume, and achieve favorable reproductive outcomes in some patients. However, adenomyotic lesions lack clear boundaries and exhibit an infiltrative interdigitation with normal myometrium. Therefore, treatment of adenomyosis requires not only a focus on symptom improvement but also the protection of vital structures, consideration of fertility needs, and long-term disease management. This review summarizes the characteristics of thermal ablation technologies, clinical decision-making, symptom control, fertility preservation, combination therapies, and safety, aiming to provide a reference for clinical practice in the thermal ablation treatment of adenomyosis.]]> 2026/9/30 9:59:15 1, Feng Xiao², Gong Xiaoming¹]]> Zhao Xiaokang¹, Feng Xiao², Gong Xiaoming¹ 4true ［Abstract］　Adenomyosis(AM) is a common benign uterine disorder in childbearing age women. It is characterized by typical clinical manifestations such as dysmenorrhea, menorrhagia, and compressive symptoms caused by uterine enlargement, with significant negative impacts on female fertility. Due to the infiltrative growth patterns of adenomyosis lesions, adenomyosis poses a persistent therapeutic challenge. Both pharmacological and conventional surgical treatments have inherent limitations. Exploring treatment modalities with fewer adverse reactions and less invasiveness has always been a clinical hotspot. Focused ultrasound ablation surgery(FUAS), also known as high-intensity focused ultrasound(HIFU) ablation, is a non-invasive therapeutic technique that has emerged in recent years. Extensive studies have confirmed its safety and efficacy. At present, it has become an important means for clinicians to treat adenomyosis and has been included in Chinese expert consensus guidelines. This review summarizes the current status and research progress of FUAS in the treatment of adenomyosis.]]> 2026/9/30 9:59:15 1, Zhang Lian²]]> Xu Feng¹, Zhang Lian² 3true ［Abstract］　Adenomyosis is a common benign uterine disease in women of reproductive age, characterized by progressively aggravated dysmenorrhea, menorrhagia, chronic pelvic pain and infertility, which seriously affects the quality of life and reproductive outcomes of patients. The etiology of adenomyosis is complex and its pathogenesis remains incompletely elucidated. Although hysterectomy remains the radical cure for adenomyosis, drug therapy plays an irreplaceable role in fertility preservation, recurrence prevention and long-term management. In recent years, significant progress has been made in drug therapies for adenomyosis. High-level evidence has accumulated regarding the efficacy, safety, and long-term management of progestogens, gonadotropin-releasing hormone(GnRH) agonists and antagonists, and selective progesterone receptor modulators(SPRMs). Furthermore, combination regimens have further optimized the balance between therapeutic efficacy and tolerability. The discovery of new targets, including prolactin receptors, and the development of targeted monoclonal antibody drugs offer new hope for refractory cases. This review summarizes the efficacy and safety of commonly used therapeutic drugs, advances in novel drug research, the development of new targets, and future research directions for adenomyosis, aiming to provide a reference for rational drug therapy and subsequent studies.]]> 2026/9/30 0:00:00 Zhu Yingjun, Yang Yinan 2true ［Abstract］　Adenomyosis is a common benign gynecological condition that severely affects the quality of life in women of reproductive age. The levonorgestrel-releasing intrauterine system(LNG-IUS) is recommended by clinical guidelines as the first-line conservative treatment for adenomyosis due to its ease of insertion and effectiveness in alleviating dysmenorrhea and reducing menstrual blood loss. However, patients with adenomyosis often present with an enlarged uterine volume, distorted uterine cavity morphology, and abnormally enhanced myometrial contractility, which significantly increase the rate of LNG-IUS expulsion after its conventional insertion. According to reports, the spontaneous expulsion rates of LNG-IUS in adenomyosis patients within one year of its insertion range from 10% to 25%. To address this challenge, various intrauterine fixation techniques for LNG-IUS have been explored in clinical practice. This paper summarizes the main methods of intrauterine LNG-IUS fixations for patients with adenomyosis, including suture fixation, the GyneFix-assisted Mirena combination ring fixation and non-suture fixation. It focuses on summarizing the specific procedures, technical advantages, limitations, and challenges associated with each technique, aiming to provide reference for clinicians in selecting appropriate fixation strategies.]]> 2026/9/30 9:59:15 Sun Yilin, Wei Weiwei, Cao Ying, Zheng Yafeng, Chen Jiming 1true